0001209191-18-023846.txt : 20180404 0001209191-18-023846.hdr.sgml : 20180404 20180404173812 ACCESSION NUMBER: 0001209191-18-023846 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180402 FILED AS OF DATE: 20180404 DATE AS OF CHANGE: 20180404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baird William D III CENTRAL INDEX KEY: 0001547658 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 18738347 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS, INC. STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-02 0 0001178879 AMICUS THERAPEUTICS INC FOLD 0001547658 Baird William D III 1 CEDAR BROOK DRIVE, C/O AMICUS THERAPEUTICS, INC. CRANBURY NJ 08512 0 1 0 0 Chief Financial Officer Common Stock 2018-04-02 4 M 0 10000 2.45 A 127662 D Common Stock 2018-04-02 4 S 0 10000 14.2648 D 117622 D Stock Options (right to buy) 2.45 2018-04-02 4 M 0 10000 0.00 D 2024-01-03 Common Stock 10000 44000 D The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.00 to $14.84. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. All of the options were fully vested and exercisable as of April 2, 2018 /s/ William D. Baird, III 2018-04-04